Fig. 1.

Study design. The DCVAC/PCa treatment consisted of, on average, 12 doses of 1 × 10⁷ DCs injected s.c. The treatment comprised an initial 7 days of metronomic cyclophosphamide administration. DCVAC/PCa was then administered every 2–6 weeks up to the maximum number of doses manufactured from one leukapheresis. Immunomonitoring (IM) was evaluated after the first, fourth, and twelfth dose or after the last dose of DCVAC/PCa if less than 12 doses were manufactured from 1 leukapheresis. Clinical evaluation was performed after every single DCVAC/PCa dose